Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients

BACKGROUND. Type 1 diabetes (T1D) results from destruction of pancreatic β cells by autoreactive effector T cells. We hypothesized that the immunomodulatory drug alefacept would result in targeted quantitative and qualitative changes in effector T cells and prolonged preservation of endogenous insul...

詳細記述

保存先:
書誌詳細
出版年:J Clin Invest
主要な著者: Rigby, Mark R., Harris, Kristina M., Pinckney, Ashley, DiMeglio, Linda A., Rendell, Marc S., Felner, Eric I., Dostou, Jean M., Gitelman, Stephen E., Griffin, Kurt J., Tsalikian, Eva, Gottlieb, Peter A., Greenbaum, Carla J., Sherry, Nicole A., Moore, Wayne V., Monzavi, Roshanak, Willi, Steven M., Raskin, Philip, Keyes-Elstein, Lynette, Long, S. Alice, Kanaparthi, Sai, Lim, Noha, Phippard, Deborah, Soppe, Carol L., Fitzgibbon, Margret L., McNamara, James, Nepom, Gerald T., Ehlers, Mario R.
フォーマット: Artigo
言語:Inglês
出版事項: American Society for Clinical Investigation 2015
主題:
Clinical Medicine
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4623571/
https://ncbi.nlm.nih.gov/pubmed/26193635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI81722
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料